Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-aminolevulinic acid + temozolomide
- Development stage
- Unknown
- Lead developer
- Alpheus Medical
- Modality
- Small Molecules
- Administration
- Oral, Implant
01
Overview
A combination therapy using 5-aminolevulinic acid (5-ALA) for fluorescence-guided resection of brain tumors and temozolomide as a chemotherapeutic agent. 5-ALA helps surgeons visualize malignant tissue during surgery by causing cancer cells to fluoresce pink under blue light, while temozolomide provides anti-tumor activity as an oral chemotherapy treatment. This combination approach aims to maximize tumor resection and improve survival outcomes in patients with gliomas.
02
Targets
DNA
Beyond the preview
Go deeper on 5-aminolevulinic acid + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-aminolevulinic acid + temozolomide.